Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Erdem

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Spinal Cord|July 12, 2017
Reliability, validity and sensitivity to change of neurogenic bowel dysfunction score in patients with spinal cord injuryD Erdem, D Hava, P Keskinoğlu, et al.
Nigerian Journal of Clinical Practice|October 27, 2017
The role of the nasal and paranasal sinus pathologies on the development of chronic otitis media and its subtypes: A computed tomography studyM Damar, A E Dinç, D Erdem, et al.
Breast (Edinburgh, Scotland)|April 14, 2026
Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposureF Kemik, T K Şahin, H Özçelik, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Spinal Cord|July 12, 2017
Reliability, validity and sensitivity to change of neurogenic bowel dysfunction score in patients with spinal cord injuryD Erdem, D Hava, P Keskinoğlu, et al.
Nigerian Journal of Clinical Practice|October 27, 2017
The role of the nasal and paranasal sinus pathologies on the development of chronic otitis media and its subtypes: A computed tomography studyM Damar, A E Dinç, D Erdem, et al.
Breast (Edinburgh, Scotland)|April 14, 2026
Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposureF Kemik, T K Şahin, H Özçelik, et al.
Pageof 2